Let's break down what the current body of research suggests
More importantly, IV glutathione is now under CDSCO regulatory scrutiny in India (May 2026) and carries a documented 32% adverse event rate
However, the research did not demonstrate a reduction in cardiac allograft vasculopathy risk
Contraindications and Clinical Cautions While generally safe, growth hormone optimization peptides are contraindicated in patients with active malignancies, as IGF-1 can promote the proliferation of existing cancer cells
What to Expect After Treatment After completing your GLP-1 weight loss treatment, your body will have experienced meaningful changes, not just in appearance, but in how it responds to hunger, metabolism, and energy use
Others feel terrible after taking it